Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 4/20 | 0.43 |
| ▸ | FEN1 | P39748 | 4/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123552 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5139628 | 0.83 | LMNA (0.63) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5251958 | 0.82 | ALDH1A1 (0.58) | SMN1; SMN2NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL5121455 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5129513 | 0.82 | KMT2A (0.64) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5121107 | 0.81 | KMT2A (0.49) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5128752 | 0.81 | KDM4E (0.53) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5128689 | 0.81 | HPGDS (0.59) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5122141 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL5121752 | 0.81 | NTRK1 (0.47) | SMN1; SMN2NPC1RAB9ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| EP-1441734-B1 | DIHYDROXYPYRIMIDINE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-02-28 | — | — | EP | disclosed |
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | DUT, DPYD, TYMP | SMN1; SMN2 4143/4885NPC1 2830/4885RAB9A 3221/4885 |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | SMN1; SMN2 4190/4885NPC1 3019/4885RAB9A 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.